Huakang Biomedical Holdings Company Limited provided consolidated earnings guidance for the six months ended 30 June 2020. Based on the information currently available to the board of directors of the Company, including the preliminary review of the latest unaudited consolidated management accounts of the Group, the Board wishes to inform the shareholders of the Company and potential investors that the Group is expected to record a loss attributable to owners of the Company of approximately RMB 6.1 million for the six months ended 30 June 2020 as compared with the profit attributable to owners of the Company of approximately RMB 223,000 for the six months ended 30 June 2019.